Dosing and Administration
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients wit
Medication Detail
Australian Public Assessment Report Reslizumab
Cinqair Reslizumab Injection
CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
TA479 Review decision paper
Teva files MAA for asthma treatment reslizumab
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab (Cinqair) Approved to Treat Severe Asthma | RT
Older Patients with Asthma Do Well with Reslizumab | RT
Israeli Pharma gets FDA Approval for Asthma Antibody
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair | Fierce Pharma
Reslizumab | Teva UK
